| Growing Edges Llc | |
|
18205 N 51st Ave Bldg 2 Suite 115 Glendale AZ 85308-1490 | |
| (602) 548-1444 | |
| (602) 548-1446 |
| Full Name | Growing Edges Llc |
|---|---|
| Speciality | Psychologist |
| Location | 18205 N 51st Ave Bldg 2, Glendale, Arizona |
| Authorized Official Name and Position | Ilyssa Swartout (PRESIDENT) |
| Authorized Official Contact | 6025481444 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Growing Edges Llc 19580 W Indian School Rd Ste 105-134 Buckeye AZ 85396-2081 Ph: (602) 548-1444 | Growing Edges Llc 18205 N 51st Ave Bldg 2 Suite 115 Glendale AZ 85308-1490 Ph: (602) 548-1444 |
| NPI Number | 1073739660 |
|---|---|
| Provider Enumeration Date | 04/18/2007 |
| Last Update Date | 09/21/2022 |
| Certification Date | 09/21/2022 |
| Medicare PECOS PAC ID | 6103818208 |
|---|---|
| Medicare Enrollment ID | O20040331000033 |
News Archive
Following two decades of research on a group of rare diseases called hypereosinophilic syndrome at Cincinnati Children's Hospital Medical Center, the U.S. Food and Drug Administration has approved the drug Nucala (mepolizumab) for use in the treatment of patients with hypereosinophilic syndrome.
Icagen, Inc. today announced that, following a review of data from recently completed clinical studies as well as the Company's proposed protocol for a Phase II clinical trial in patients with treatment resistant epilepsy, the FDA has notified the Company that the clinical hold on Icagen's IND for ICA-105665, a novel orally available small molecule KCNQ potassium channel agonist, has been removed.
Research published in Nature by the Korea Advanced Institute of Science (KAIST) found that lymphatic vessels in the scull involved in the clearance of cerebrospinal fluid often become compromised with age. This finding was only possible through advances in imaging technology.
A Florida State University College of Medicine researcher has been awarded two separate grants from the National Institutes of Health (NIH) totaling $2.4 million to continue her work in detecting autism in children as young as 18 months.
Bristol-Myers Squibb Company and Pfizer announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073739660 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | (* (Not Available)) | Primary |
| Provider Name | Ilyssa P Swartout |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1881630325 PECOS PAC ID: 5991797094 Enrollment ID: I20040414001195 |
News Archive
Following two decades of research on a group of rare diseases called hypereosinophilic syndrome at Cincinnati Children's Hospital Medical Center, the U.S. Food and Drug Administration has approved the drug Nucala (mepolizumab) for use in the treatment of patients with hypereosinophilic syndrome.
Icagen, Inc. today announced that, following a review of data from recently completed clinical studies as well as the Company's proposed protocol for a Phase II clinical trial in patients with treatment resistant epilepsy, the FDA has notified the Company that the clinical hold on Icagen's IND for ICA-105665, a novel orally available small molecule KCNQ potassium channel agonist, has been removed.
Research published in Nature by the Korea Advanced Institute of Science (KAIST) found that lymphatic vessels in the scull involved in the clearance of cerebrospinal fluid often become compromised with age. This finding was only possible through advances in imaging technology.
A Florida State University College of Medicine researcher has been awarded two separate grants from the National Institutes of Health (NIH) totaling $2.4 million to continue her work in detecting autism in children as young as 18 months.
Bristol-Myers Squibb Company and Pfizer announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
› Verified 9 days ago
News Archive
Following two decades of research on a group of rare diseases called hypereosinophilic syndrome at Cincinnati Children's Hospital Medical Center, the U.S. Food and Drug Administration has approved the drug Nucala (mepolizumab) for use in the treatment of patients with hypereosinophilic syndrome.
Icagen, Inc. today announced that, following a review of data from recently completed clinical studies as well as the Company's proposed protocol for a Phase II clinical trial in patients with treatment resistant epilepsy, the FDA has notified the Company that the clinical hold on Icagen's IND for ICA-105665, a novel orally available small molecule KCNQ potassium channel agonist, has been removed.
Research published in Nature by the Korea Advanced Institute of Science (KAIST) found that lymphatic vessels in the scull involved in the clearance of cerebrospinal fluid often become compromised with age. This finding was only possible through advances in imaging technology.
A Florida State University College of Medicine researcher has been awarded two separate grants from the National Institutes of Health (NIH) totaling $2.4 million to continue her work in detecting autism in children as young as 18 months.
Bristol-Myers Squibb Company and Pfizer announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
› Verified 9 days ago
A New Leaf Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 8581 N 61st Ave, Building A, Suite 101-102, Glendale, AZ 85302 Phone: 623-934-1991 Fax: 623-878-9335 | |
Enhance Counseling & Wellness Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 17431 N 71st Dr Ste 101, Glendale, AZ 85308 Phone: 623-680-3469 Fax: 623-248-3389 | |
Center For Couples Therapy, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 18205 N 51st Ave, Ste 113, Glendale, AZ 85308 Phone: 623-999-7368 | |
Renewed Path Behavioral Health Consulting Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 7112 N 55th Dr Ste B, Glendale, AZ 85301 Phone: 602-727-4431 | |
Family Life Behavioral Health Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6610 N 47th Ave Ste 4, Glendale, AZ 85301 Phone: 623-206-7541 | |
Healing Hartze Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 17505 N 79th Ave Ste 105, Glendale, AZ 85308 Phone: 602-989-8899 Fax: 602-900-0969 | |
2nd Chance Behavioral Health Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 10620 N 43rd Ave Ste 10, Glendale, AZ 85304 Phone: 602-860-0044 Fax: 602-848-3186 |